Algeta’s Bayer Buyout: Assessing A Rare Case of Partner Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Few biotechs are acquired by their partners -- only about a half dozen in each of the last two years, making the Bayer acquisition of Algeta an exception to the rule. Like other recent billion-dollar partner acquisitions, expectations for subsequent performance seem high.